BRAF and neoplasm: It is also possible to recognize some immunohistochemical features related to MMR status and BRAF mutations, in particular: a reduction in CDX2 staining, related to adverse prognosis, is present both in BRAFmt/MSI and BRAFmt/MSS CRCs [90, 91]; CK20 expression is preserved in BRAFmt/MSS [30] as in BRAFwt, but lost in BRAFmt/MSI CRCs CRCs [30, 90, 91]; CK7 is only minimally expressed in CRCs [92] but is frequently upregulated in BRAFmt/MSS CRCs [30] interestingly in tumor budding regions [93].